Clinical Trial Update: Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase II study of ipilimumab monotherapy in recurrent platinum-sensitive ovarian cancer completed; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line | Phase 2 | Status: COMPLETED | Results posted: 2016-04-19